InfluenzaSICS Editore, 01.10.2014 In the Northern Hemisphere, seasonal influenza epidemics usually occur during the winter (”the flu season”) with the peak typically around January and February. At-risk groups should be vaccinated annually well in advance (October–November) before the start of the expected influenza epidemic. National public health organizations issue recommendations of groups to whom annual influenza vaccination should be offered (possibly free of charge), i.e. of individuals whose health would be essentially threatened by influenza or who would gain significant health benefit from influenza vaccination. Influenza can be diagnosed on the basis of the clinical presentation combined with a confirmed epidemic circulating in the community, or on the basis of virological (rapid) diagnostic test results. The treatment of influenza in a healthy adult patient is generally symptomatic. Antiviral agents should be considered for children, pregnant women, patients with exceptionally severe symptoms and those belonging to at-risk groups. The sooner the drug therapy is started, the better the effect. Treatment should be started within 48 hours of symptom onset. |
Häufige Begriffe und Wortgruppen
alanine transaminase anaemia antiviral drug Assessment asthma atrial fibrillation bacterial basisof body of evidence Chronic Cochrane Database Syst Cochrane review COPD coronary heart disease cough Database Syst Rev diabetes diagnosis downgraded by study EBM Guidelines effect lies close estimate of effect Evidence Based Medicine evidence is downgraded Evidence Summaries Evidence-Based Medicine FLUVAC healthy adults hemiblock hospitalisation inactivated vaccine included 75 studies infections influenza epidemic influenza in healthy influenza vaccination influenza viruses influenza-like illness inthe Latin MediDSS narcolepsy Neuraminidase inhibitors NNTB NNTH non-steroidal anti-inflammatory drug number needed ofinfluenza oseltamivir Oseltamivir significantly otitis media outcome patients Pietrantonj placebo Polycystic ovary syndrome preventing influenza primary prophylaxis pulmonary quality of evidence reduced the risk respiratory review 1 included Seasonal influenza significantly reduced sinusitis symptom onset symptomatic syndrome tachycardia therapy Therewas transaminase aminotransferase treating influenza treatment trials true effect unverified pneumonia Vaccines for preventing viral circulation Virus type witha zanamivir Zanamivir reduced